US FDA panel calls for clarity on duration of bone drug use, but sets no cutoff
This article was originally published in SRA
Executive Summary
Advisors to the US Food and Drug Administration deliberating over the safety and effectiveness of using bisphosphonates to prevent and treat osteoporosis have voted (17-6) in favour of clarifying the duration of use on the labels of such drugs. The recommendation, made on 9 September, however, fell short of specifying a particular limit1,2.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.